Nucleus Genomics Lands $14M

Nucleus is linking DNA to health outcomes.

The latest: The genomics startup secured $14M in a Series A led by Seven Seven Six and Founders Fund, bringing total funding to $32M.

Decoded. Streamlining 70K+ genetic tests into one, Nucleus aims to make clinical-grade DNA insights widely accessible.

For $399, consumers receive comprehensive genetic health analysis through an at-home cheek swab — screening for risk of major conditions like heart disease, cancer, and Alzheimer’s.

Growth mode. Ramping up, its user base tripled since last fall, with revenue climbing 68% MoM while expanding genetic analysis capabilities from 10 to 800+ conditions.

Alongside new capital, Nucleus announced the acquisition of AI platform Cambrean, combining DNA insights with wearable data to deliver personalized recommendations.

Bringing whole-genome sequencing into standard care practices, it’s also kicking off clinical partnerships starting with preventative health platform Bionic Health.

Looking ahead: Building an integrated platform, Nucleus aims to make genome sequencing as foundational as blood tests. Scaling beyond DTC tests, delivering better health outcomes is the next proof point.